In a randomized, placebo- and active-controlled trial involving 2463 postmenopausal women with osteoporosis, Miller and colleagues compared treatment with subcutaneous abaloparatide—a novel selective activator of the parathyroid hormone type 1 receptor—with placebo or open-label teriparatide for the prevention of new vertebral fractures. The authors report that compared with placebo, use of abaloparatide reduced the risk of new vertebral and nonvertebral fractures over 18 months. In an Editorial, Cappola and Shoback discuss treatment to reduce fracture risk among postmenopausal women.
Highlights. JAMA. 2016;316(7):685-687. doi:10.1001/jama.2015.14432